NCT04782297 (LTHD PMCF) is a clinical trial of Long term hemodialysis catheter in CKD, sponsored by Medical Components, Inc dba MedComp.

Who is sponsoring NCT04782297?

NCT04782297 is sponsored by Medical Components, Inc dba MedComp.

What drugs are being tested in NCT04782297?

Interventions in NCT04782297: Long term hemodialysis catheter.

Is NCT04782297 still recruiting?

NCT04782297 is currently withdrawn. Last updated 10 January 2024.

Last reviewed 2024-01-10 · How we verify

NCT04782297: LTHD PMCF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)

Withdrawn Last updated 10 January 2024

What this trial tests

trial testing Long term hemodialysis catheter in CKD. Withdrawn.

Timeline

30 March 2022

Primary endpoint
17 March 2023

17 March 2023

Quick facts

Lead sponsor	Medical Components, Inc dba MedComp
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	30 March 2022
Primary completion	17 March 2023
Estimated completion	17 March 2023
Sites	2 locations across United States, Spain

Drugs / interventions tested

Long term hemodialysis catheter

Conditions studied

CKD — all drugs for CKD →
ESRD — all drugs for ESRD →

Sponsor

Medical Components, Inc dba MedComp

Who can join

18 and older, any sex, with CKD or ESRD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this observational PMCF study is to collect clinical data on the safety and efficacy of Medcomp Long Term Hemodialysis (LTHD) Catheter Kits in compliance with MDR 2017/745.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for CKD

Currently open trials in the same condition.

NCT07312981 — The CPH-MBD Cohort Dietary Substudy - Comparison of Methods for Dietary Registrations · recruiting
NCT06892249 — Suitability of Two Flavours of a High-energy, Low-protein Formula (Renalive® LP) in Chronic Kidney Disease Stage 3b-5 Ou · NA · recruiting
NCT07062952 — Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery · NA · recruiting
NCT07182942 — The Effect and Mechanism of Xiqing Regulating Intestinal Homeostasis on Drug Efficacy of Chronic Kidney Disease · Phase 4 · recruiting
NCT06775028 — Integrated Approach in Frail Older People with Atrial Fibrillation · NA · recruiting

Other Medical Components, Inc dba MedComp trials

Trials by the same sponsor.

NCT04787926 — DuraLock-C Catheter Lock Solution · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04782297 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical Components, Inc dba MedComp
Last refreshed: 10 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04782297.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing